Integra LifeSciences (IART) faces its Q3 2026 earnings release on October 21, with consensus EPS estimates near $0.56. The primary driver supporting the 79.5% market-implied probability of a beat is the company’s October 2 preliminary guidance, which placed adjusted EPS in the $0.55–$0.59 range—centering at or above consensus—despite revenue expectations of $410–412 million falling short of analyst targets around $416 million. This follows a strong Q2 beat of $0.56 versus $0.48 consensus and a track record of outperforming EPS estimates in seven of the prior eight quarters. The outlook was tempered by July flooding at the Cincinnati facility, which prompted lowered full-year 2026 revenue and adjusted EPS guidance, yet management highlighted ongoing supply recovery, product relaunches, and robust operating cash flow projections as offsetting factors. Traders appear to weigh the EPS guidance midpoint and historical execution more heavily than the revenue shortfall in pricing the outcome.